Florence Breast 2023
The availability of new therapeutic measures raises the important question on how to integrate them w/ local and regional treatments, particularly with radiation therapy, in both curative and advanced settings
The purpose of this consensus is to provide preclinical and clinical evidence – and consensus-based guidelines on how to integrate targeted and other agents properly and safely with irradiation to improve the clinical care of patients affected by breast cancer who are candidates for these treatments. An international panel of experts in preclinical and translational research, drug development, and radiation therapy reviewed the available evidence and will summarize in the beautiful city of Florence recommendations to help physicians in daily clinical practice.
CDK 4/6 inhibitors
|
|
Anti HER2 Therapy (non ADCs)
|
|
Innovations in Medical & Radiation Oncology
|
|
Antibody Drug Conjugates (ADC's)
|
|
Preclinical & Clinical Trials Managements
|
|
Interaction between metastatic Risk/efficiency of systemic Tx & effects on loco regional Tx on Survival & Patient Advocate involvement in the design and conduct of breast cancer clinical trials
|
|
PreClinical
|
Immunotherapy
|
|
PARP Inhibitors
|
|